Precigen (PGEN) Preferred Stock Liabilities (2011 - 2013)
Precigen (PGEN) reported Preferred Stock Liabilities of $35.2 million for Q2 2013, down 83.34% quarter-over-quarter from $211.4 million in Q4 2012.
Precigen (PGEN) Preferred Stock Liabilities (2011 - 2013) Analysis & Trends
Precigen (PGEN) has 3 years of Preferred Stock Liabilities data on file, last reported at $35.2 million in Q2 2013.
- Preferred Stock Liabilities for Q2 2013 came in at $35.2 million, changed N/A year-over-year; the trailing twelve-month figure through Jun 2013 was $35.2 million (changed N/A YoY), and the FY2012 annual result was $211.4 million, up 79.22% from the prior year.
- Preferred Stock Liabilities declined to $35.2 million in Q2 2013 per PGEN's latest filing, from $211.4 million in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $211.4 million in Q4 2012 and troughed at $35.2 million in Q2 2013.
- A 3-year average of $121.5 million and a median of $118.0 million in 2011 frame the typical range for Preferred Stock Liabilities.
- On a YoY basis, Preferred Stock Liabilities climbed as much as 79.22% in 2012 and fell as far as 79.22% in 2012.
- A 3-year view of Preferred Stock Liabilities shows it stood at $118.0 million in 2011, then jumped by 79.22% to $211.4 million in 2012, then tumbled by 83.34% to $35.2 million in 2013.
- Business Quant data shows PGEN's Preferred Stock Liabilities at $35.2 million in Q2 2013, $211.4 million in Q4 2012, and $118.0 million in Q4 2011.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | - |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Precigen | 1.32 Bn | 1.32 Bn | 20.69 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2013 | 35.23 Mn |
| Dec 31, 2012 | 211.40 Mn |
| Dec 31, 2011 | 117.95 Mn |